officially retracts the article entitled, “Silencing of MEOX1 Gene Inhibits Proliferation and Promotes Apoptosis of LNCaP Cells in Prostate Cancer” by Zhi-Yuan Zhu, Xiao-Le Wang, and Da-Peng Li (Cancer Biother Radiopharm. 2019;34(2):91–102; doi:10.1089/cbr.2018.2545) due to oddly styled Western blots in Figs. 3B and 4B and questionable flow-cytometry results in Fig. 7A in the article. These issues were originally questioned in a comment on the PubPeer platform in 20201 but were again reported as being part of a large paper mill in September 2021.2
The corresponding author, Dr. Da-Peng Li, did not respond to requests for the raw data as it pertained to the work for further examination.
Submission of manuscripts from a paper mill is a violation of the journal's standard protocols and is considered an infraction against the rigorous standards of scientific publishing.
The Editor and Publisher of Cancer Biotherapy and Radiopharmaceuticals are committed to preserving the scientific literature and the community it serves and does not tolerate any misconduct.
References
1. PubPeer. https://pubpeer.com/publications/63EE8FBAB07C8B0F8AEC1A1EABC66F Last accessed October 4, 2021.
2. Smut C. The scientific sea of miR- and exosome-related knowledge. For Better Science. Sept 22, 2021; https://forbetterscience.com/2021/09/22/the-scientific-sea-of-mir-and-exosome-related-knowledge/ Last accessed October 4, 2021.
Get full access to this article
View all access options for this article.
References
1.
BrayF, Lortet-TieulentJ, FerlayJ, et al.Prostate cancer incidence and mortality trends in 37 European countries: An overview. Eur J Cancer, 2010; 46:3040.
2.
ZhangL, WuS, GuoLR, et al.Diagnostic strategies and the incidence of prostate cancer: Reasons for the low reported incidence of prostate cancer in China. Asian J Androl, 2009; 11:9.
3.
HuncharekM, HaddockKS, ReidR, et al.Smoking as a risk factor for prostate cancer: A meta-analysis of 24 prospective cohort studies. Am J Public Health, 2010; 100:693.
4.
WilsonKM, KasperzykJL, RiderJR, et al.Coffee consumption and prostate cancer risk and progression in the Health Professionals Follow-up Study. J Natl Cancer Inst, 2011; 103:876.
5.
LeitzmannMF, RohrmannS. Risk factors for the onset of prostatic cancer: Age, location, and behavioral correlates. Clin Epidemiol, 2012; 4:1.
6.
FriedlanderJI, DutyBD, OkekeZ, et al.Obstructive uropathy from locally advanced and metastatic prostate cancer: An old problem with new therapies. J Endourol, 2012; 26:102.
7.
ZhangHL, YangLF, ZhuY, et al.Serum miRNA-21: Elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate, 2011; 71:326.
8.
FizaziK, CarducciM, SmithM, et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet, 2011; 377:813.
9.
HeidenreichA, BastianPJ, BellmuntJ, et al.EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol, 2014; 65:467.
10.
IbrahimT, FlaminiE, MercataliL, et al.Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer, 2010; 116:1406.
11.
LeeRJ, SaylorPJ, SmithMR. Treatment and prevention of bone complications from prostate cancer. Bone, 2011; 48:88.
12.
DashR, AzabB, ShenXN, et al.Developing an effective gene therapy for prostate cancer: New technologies with potential to translate from the laboratory into the clinic. Discov Med, 2011; 11:46.
13.
TomlinsSA, BjartellA, ChinnaiyanAM, et al.ETS gene fusions in prostate cancer: From discovery to daily clinical practice. Eur Urol, 2009; 56:275.
14.
NakashimaN, HuangCL, LiuD, et al.Intratumoral Wnt1 expression affects survivin gene expression in non-small cell lung cancer. Int J Oncol, 2010; 37:687.
15.
BayrakliF, GucluB, YakicierC, et al.Mutation in MEOX1 gene causes a recessive Klippel-Feil syndrome subtype. BMC Genet, 2013; 14:95.
16.
DouvilleJM, CheungDY, HerbertKL, et al.Mechanisms of MEOX1 and MEOX2 regulation of the cyclin dependent kinase inhibitors p21 and p16 in vascular endothelial cells. PLoS One, 2011; 6:e29099.
17.
ChoiMY, RomerAI, WangY, et al.Requirement of the tissue-restricted homeodomain transcription factor Nkx6.3 in differentiation of gastrin-producing G cells in the stomach antrum. Mol Cell Biol, 2008; 28:3208.
18.
SuhYA, ArnoldRS, LassegueB, et al.Cell transformation by the superoxide-generating oxidase Mox1. Nature, 1999; 401:79.
19.
ThiavilleMM, StoeckA, ChenL, et al.Identification of PBX1 target genes in cancer cells by global mapping of PBX1 binding sites. PLoS One, 2012; 7:e36054.
20.
SunL, BurnettJ, GasparyanM, et al.Novel cancer stem cell targets during epithelial to mesenchymal transition in PTEN-deficient trastuzumab-resistant breast cancer. Oncotarget, 2016; 7:51408.
KelkarMG, ThakurB, DerleA, et al.Tumor suppressor protein p53 exerts negative transcriptional regulation on human sodium iodide symporter gene expression in breast cancer. Breast Cancer Res Treat, 2017; 164:603.
23.
XuJ, LuMX, CuiYD, et al.Selection and evaluation of reference genes for expression analysis using qRT-PCR in Chilo suppressalis (Lepidoptera: Pyralidae). J Econ Entomol, 2017; 110:683.
24.
SathyanarayanaUG, PadarA, SuzukiM, et al.Aberrant promoter methylation of laminin-5-encoding genes in prostate cancers and its relationship to clinicopathological features. Clin Cancer Res, 2003; 9:6395.
25.
LinHY, KuoYC, WengYI, et al.Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent. Prostate, 2012; 72:1767.
26.
PotoskyAL, DavisWW, HoffmanRM, et al.Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst, 2004; 96:1358.
27.
CollinsAT, BerryPA, HydeC, et al.Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res, 2005; 65:10946.
28.
PengC, LouHL, LiuF, et al.Enhanced identification of potential pleiotropic genetic variants for bone mineral density and breast cancer. Calcif Tissue Int, 2017; 101:489.
29.
DavidsonBL, McCrayPBJr. Current prospects for RNA interference-based therapies. Nat Rev Genet, 2011; 12:329.
30.
PecotCV, CalinGA, ColemanRL, et al.RNA interference in the clinic: Challenges and future directions. Nat Rev Cancer, 2011; 11:59.
31.
LiCM, GuoM, BorczukA, et al.Gene expression in Wilms' tumor mimics the earliest committed stage in the metanephric mesenchymal-epithelial transition. Am J Pathol, 2002; 160:2181.
32.
AlvaradoDM, HawkinsRD, BashiardesS, et al.An RNA interference-based screen of transcription factor genes identifies pathways necessary for sensory regeneration in the avian inner ear. J Neurosci, 2011; 31:4535.
33.
ZhangL, XiaL, ZhaoL, et al.Activation of PAX3-MET pathways due to miR-206 loss promotes gastric cancer metastasis. Carcinogenesis, 2015; 36:390.
34.
PhelanSA, ItoM, LoekenMR. Neural tube defects in embryos of diabetic mice: Role of the Pax-3 gene and apoptosis. Diabetes, 1997; 46:1189.
35.
Wild-BodeC, WellerM, WickW. Molecular determinants of glioma cell migration and invasion. J Neurosurg, 2001; 94:978.
